Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children

University of British Columbia167 enrolled

Overview

The purpose of this study is to compare the safety and effectiveness (immune response) to one or two doses of adjuvanted H1N12009 influenza vaccine in young children. An adjuvant is an additive that can boost the immune response. The study will enroll 300 children (ages 6-35 months). Participants will receive 2 doses of adjuvanted H1N12009 vaccine 3 weeks apart. Study procedures include: medical history, blood samples and completing a memory aid. Participants will be involved in study related procedures for approximately 6 weeks.

The goal of this study is to determine if one or two doses of the H1N12009 influenza vaccine are needed in young children, a population group at high risk of influenza infection and subsequent hospitalization. The objectives of this study are two-fold: 1. To compare the safety and immunogenicity of 1 and 2 doses of adjuvanted H1N12009 influenza vaccine in children 6-35 months of age. 2. To conduct the trial soon after the vaccines become available and share the observations with health officials and the public as soon as possible.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

167

Conditions

Influenza

Interventions

adjuvanted ArepanrixBIOLOGICAL

Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 35 MonthsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent provided for the subject by a parent or legal guardian * Children age 6-35 months Exclusion Criteria: * Allergies to eggs, thimerosal, gentamicin sulphate or latex * Life-threatening reaction to previous Flu vaccine * Bleeding disorder * Pregnancy * Receipt of blood or blood products in past 3 months * Chronic illness that could interfere with trial participation * Compromised immune system * Previous lab-confirmed H1N12009 infection * Receipt of H1N12009 vaccine * Receipt of Seasonal Influenza vaccine since March 2009

Locations (6)

Alberta Children's Hospital, University of Calgary

Calgary, Alberta, Canada

Child and Family Research Institute

Vancouver, British Columbia, Canada

Vaccine Evaluation Center, University of British Columbia

Vancouver, British Columbia, Canada

Canadian Center for Vaccinology, Dalhousie University

Halifax, Nova Scotia, Canada

Outcomes

Primary Outcomes

Safety and immunogenicity of one and two doses Arepanrix

To compare the safety and immunogenicity of one and two doses of adjuvanted H1N12009 pandemic vaccine in children 6-35 months of age

Time frame: Day 7 and Day 21 post vaccination measured at day 42

Rapid Trial

To conduct this trial soon after the vaccines become available and share observations with health officials and the public as soon as possible

Time frame: Day 42

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.